Vir (VIR), Glaxo’s Xevudy Wins EC Approval for COVID-19 Posted byZacks Equity Research December 20, 2021 Leave a comment on Vir (VIR), Glaxo’s Xevudy Wins EC Approval for COVID-19 Vir Biotechnology, Inc. (VIR) and partner GlaxoSmithKline obtain the European Commission’s nod for Xevudy for the early treatment of COVID-19.